What the FDA labels say about taking them together
Macitentan and rifampin
Macitentan's FDA label of April 11, 2025 names rifampin in its drug interactions section; the rifampin label PlainMeds reads does not name macitentan. The macitentan label: “DRUG INTERACTIONS Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT.”
Check it at the source: the macitentan FDA label on DailyMed (effective April 11, 2025, Actelion Pharmaceuticals US, Inc.); the rifampin FDA label on DailyMed (effective February 11, 2026, Lupin Pharmaceuticals, Inc.).
What does the macitentan label say about rifampin?
Macitentan label, drug interactionsDRUG INTERACTIONS Strong CYP3A4 inducers (rifampin) reduce exposure to macitentan: avoid co-administration with OPSUMIT ( 7.1 , 12.3 ).
Source: FDA drug label (OPSUMIT), Actelion Pharmaceuticals US, Inc., effective April 11, 2025 (SPL set 1e484a50-55db-4b85-8c57-6cd1b0353abd), via openFDA; the full label on DailyMed
What does the rifampin label say about macitentan?
Rifampin's label (effective February 11, 2026) does not name macitentan in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (rifampin), Lupin Pharmaceuticals, Inc., effective February 11, 2026 (SPL set b56004f0-f23d-47f6-80c7-39884fccbccc), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Macitentan | Rifampin | |
|---|---|---|
| Labeled for | Pulmonary arterial hypertension | n/a |
| Boxed warning | Yes | No |
| Pharmacy cost (NADAC) | n/a | $0.679 per capsule 300 mg capsule |
| Shortage now | No current entry | In shortage |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once